Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBITDA Margin (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBITDA Margin for 5 consecutive years, with 400.57% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA Margin changed N/A year-over-year to 400.57%, compared with a TTM value of 447.63% through Sep 2025, up 190218.0%, and an annual FY2024 reading of 2182.25%, up 950662.0% over the prior year.
  • EBITDA Margin was 400.57% for Q3 2025 at Autolus Therapeutics, down from 138.37% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 1971.96% in Q1 2022 and bottomed at 279410.0% in Q4 2024.
  • Average EBITDA Margin over 4 years is 36816.41%, with a median of 589.51% recorded in 2024.
  • The sharpest move saw EBITDA Margin crashed -461669bps in 2023, then soared 212363bps in 2024.
  • Year by year, EBITDA Margin stood at 1971.96% in 2022, then crashed by -746bps to 12730.54% in 2023, then plummeted by -2095bps to 279410.0% in 2024, then skyrocketed by 100bps to 400.57% in 2025.
  • Business Quant data shows EBITDA Margin for AUTL at 400.57% in Q3 2025, 138.37% in Q2 2025, and 657.9% in Q1 2025.